Why Some Medtech Companies Stall — And How to Fix Them

You cleared the FDA. You closed a funding round. You have a product that genuinely improves patient outcomes. By every early-stage measure, you've done the hard part.

So why isn't the revenue curve moving?

After 37 years working alongside medical device and life science companies — from early-stage startups to multi-national category leaders — I've watched this scenario play out more times than I can count. And in nearly every case, the culprit isn't the technology, the market, or the timing. It's something hiding in plain sight inside the organization itself.

The Real Diagnosis

Most stalled medtech companies share four symptoms.

Strategic misalignment. Sales, clinical, and operations are each working hard — just not in the same direction. The strategy exists in a document somewhere, but it hasn't become the shared language of the team. When people aren't pulling together, momentum dies at the seams between departments.

Reactive planning. Early-stage companies are conditioned to sprint — respond to the investor, react to the competitive threat, chase the inbound lead. That agility is a strength, until it becomes the default operating mode. Without a forward-looking strategic plan that the whole leadership team genuinely co-owns, execution stalls every time the next crisis arrives.

Disengaged talent. Gallup research consistently shows that roughly 70% of employees are not fully engaged at work. In a 30-person medtech company, that's 20 people running at half capacity. The engagement crisis isn't a culture cliché — it's a direct drag on your revenue and your runway.

Channel and market confusion. FDA clearance answers the clinical question. It doesn't tell you which customer segment to enter first, which distribution partners to trust, or how to translate your clinical evidence into the economic and outcomes language that hospital value analysis committees actually respond to. Many strong products stall here, not because the market doesn't want them, but because the market hasn't been reached in the right way.

The Fix Isn't What You Think

Most founders reach for a tactical answer — a new VP of Sales, a revised pitch deck, a broader distribution agreement. Those moves can help. But if the underlying strategic architecture is weak, tactics only accelerate the noise.

What actually works is building the plan from the inside out: starting with an honest leadership self-assessment, developing a clear and altruistic vision that your entire team can rally around, and cascading that vision into goals, strategies, and tactics that every person in the organization understands and owns.

When a team co-creates a plan with genuine shared ownership, something shifts. Momentum builds faster than the tactics alone can explain. I've seen organizations hit 100% of their annual objectives even when only half their planned strategies were fully implemented — because the collective intention itself was doing much of the work.

The Fractal Executive Advantage

For many early-stage medtech companies, the answer isn't a full-time C-suite hire. It's a seasoned fractional executive who has navigated this terrain before — someone who can step in, run the strategic planning process, align the team, and build the execution infrastructure, without the overhead of a permanent hire.

The companies that break through the plateau aren't always the ones with the best technology or the deepest pockets. They're the ones with the clearest direction, the most aligned teams, and a leader who knows how to turn a great plan into a great culture.

That's where transformation begins.

Terry Murray is Founder and Principal of Performance Transformation, Inc., and the author of The Transformational Entrepreneur. He partners with medical device and life science companies as a fractional executive, specializing in strategic planning, AI strategy, sales channel development, rapid valuation growth, and M&A preparation. Learn more at performtransform.com or reach out to schedule a quick assessment call at terry@performtransform.com.